hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06310785 id: TJ-IRB20231191 briefTitle: Esketamine Anesthesia in Thoracic Surgery overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2024-08-31 date: 2024-08-31 date: 2024-03-15 date: 2024-03-15 name: Hui Xu class: OTHER briefSummary: Esketamine group was induced with esketamine 0.5 mg/kg, propofol 2 mg/kg, and rocuronium bromide 0.9 mg/kg. Anesthesia is maintained with propofol 5 mg/kg/h and esketamine 0.5 mg/kg/h. Anesthesia induction in the opioid group Sufentanil 0.5 ug/kg, propofol 2 mg/kg, rocuronium bromide 0.9 mg/kg. Anesthesia is maintained with propofol 5 mg/kg/h and remifentanil 1 ug/kg/h. conditions: General Anesthesia conditions: Thoracic Surgery studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: DOUBLE maskingDescription: Neither the patients who participated in the trial nor the analysis of the results of the study were aware of the experimental group whoMasked: PARTICIPANT whoMasked: OUTCOMES_ASSESSOR count: 84 type: ESTIMATED name: Esketamine name: Sufentanil measure: Dynamic compliance of the ventilator-side lung during 30 minutes of one-lung ventilation during operation measure: Lung compliance during double lung ventilation during operation measure: Compliance of the ventilator-side lung during one-lung ventilation during operation measure: Blood pressure measure: Heart rate measure: Blood gas analysis results measure: Serum inflammatory factor levels measure: cognitive function measure: Postoperative nausea and vomiting measure: Depression and anxiety measure: Postoperative pain sex: ALL minimumAge: 18 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06310772 id: NSF 2304297 briefTitle: Assessing Comorbidities in Epilepsy Using Eye Movement Recordings acronym: ACER overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2025-03-01 date: 2025-03-01 date: 2024-03-15 date: 2024-03-15 name: Eysz, Inc. class: INDUSTRY name: Wake Forest University Health Sciences name: Children's Hospital of Orange County name: University of Colorado, Denver briefSummary: This study wants to make it easier to find kids with a type of epilepsy called childhood absence epilepsy (CAE) who might have problems with ongoing seizures and thinking. Right now, doctors use tests that can be expensive and take a long time. Eysz is developing a system that looks at how kids move their eyes which might help find CAE more quickly and accurately. This study will compare Eysz with the usual tests to see if it can predict seizures and thinking problems in kids with CAE. The goal is to find these problems earlier and help kids do better in school and life. conditions: Childhood Absence Epilepsy conditions: Absence Seizures conditions: Epilepsy Comorbidities studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 60 type: ESTIMATED measure: Eye Movements to Diagnose CAE measure: Eye Movements to Diagnose Attention challenges sex: ALL minimumAge: 4 Years maximumAge: 12 Years stdAges: CHILD facility: Children's Hospital Orange County city: Orange state: California zip: 92868 country: United States lat: 33.78779 lon: -117.85311 facility: Wake Forest Baptist Health city: Winston-Salem state: North Carolina zip: 27157 country: United States lat: 36.09986 lon: -80.24422 hasResults: False
nctId: NCT06310746 id: HLX6018-FIH101 briefTitle: A Randomized, Double-Blind, Placebo-Controlled, Single-Dose Escalation Phase I Clinical Study to Assess the Safety, Pharmacokinetics, and Immunogenicity of HLX6018 in Healthy Subjects overallStatus: NOT_YET_RECRUITING date: 2024-04-30 date: 2025-12-30 date: 2026-12-30 date: 2024-03-15 date: 2024-04-04 name: Shanghai Henlius Biotech class: INDUSTRY briefSummary: The purpose of this study is to investigate the safety, PK, and immunogenicity of a single intravenous administration of HLX6018 in healthy subjects, based on the preliminary efficacy and safety established through in vitro and in vivo experiments.
This is a randomized, double-blind, placebo-controlled study with single dose escalation design to assess the safety, PK, and immunogenicity of HLX6018 in healthy subjects. It is planned to enroll 8-10 subjects in each of seven dose groups (0.25 mg/kg, 1.0 mg/kg, 4.0 mg/kg, 12 mg/kg, 25 mg/kg, 50 mg/kg, and 70 mg/kg). This is the first-in-human study of the investigational product. conditions: IPF studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: SEQUENTIAL primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 66 type: ESTIMATED name: GARP/TGF-β1 monoclonal antibody name: Placebo measure: The number of subjects experiencing adverse events (AEs) and serious adverse events (SAEs) measure: AUC0-inf measure: Cmax measure: Tmax measure: T1/2 measure: CL measure: λz sex: ALL minimumAge: 18 Years maximumAge: 55 Years stdAges: ADULT hasResults: False
nctId: NCT06310733 id: REC 66-517-1-1 briefTitle: The Effects of Probiotics, Lactobacillus GG, in the Treatment of Abdominal Pain in Children With Functional Abdominal Pain Disorders overallStatus: RECRUITING date: 2024-03-21 date: 2025-12-31 date: 2026-02-20 date: 2024-03-15 date: 2024-03-18 name: Prince of Songkla University class: OTHER briefSummary: Recurrent or chronic abdominal pain is one of the common gastrointestinal problems in children. While most children do not have organic origins (so called functional abdominal pain disorders; FAPDs), the symptoms can nevertheless be severe enough to impair the patient's quality of life, growth, and development. To help rule out organic disorders and diagnose this condition, some individuals underwent multiple invasive and costly studies.
Generally, the diagnosis of FAPDs is based on clinical symptoms and criteria, it can be divided into irritable bowel syndrome (IBS), abdominal migraine, functional abdominal pain (FAP) and functional dyspepsia (FD). Approximately 14% of children globally, between the ages of 4 and 18, experience functional abdominal pain issues8. In Thailand, the prevalence of FAPDs among adolescents (mean age of 16 years) was 5.3%, functional dyspepsia and irritable bowel syndrome were found to be the most prevalent subtypes.
It is widely known that the diversity of gut microbiota depends on multiple factors including ethnicity, mode of delivery, dietary and environmental factors. However, the studies on the use of probiotics in pediatric patients with FAPDs have been mainly conducted in western countries. Since there are limited studies on the effectiveness of probiotics in Asian children with FAPDs, the investigators aim to evaluate the effects of probiotics, LGG, in the treatment of children who suffered from FAPDs.
The secondary objectives are to measure daily pain score in children with and without FAPDs, to evaluate and compare the diversity of fecal microbiota in children with FAPDs and those without FAPDs, and to compare the diversity of fecal microbiota between children with FAPDs who took probiotics and those who did not. conditions: Functional Abdominal Pain Syndrome studyType: INTERVENTIONAL phases: PHASE4 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: TRIPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: OUTCOMES_ASSESSOR count: 54 type: ESTIMATED name: LGG name: Placebo measure: The response rate of 4 week-probiotics (LGG) on the severity of abdominal pain (number of episodes or the intensity of pain), compared to the conventional treatment, in children who suffered from FAPDs measure: The response rate of 4 week-probiotics (LGG) on the severity of abdominal pain (number of episodes or the intensity of pain), compared to the conventional treatment, in children who suffered from FAPDs measure: The response rate of 4 week-probiotics (LGG) on the severity of abdominal pain (number of episodes or the intensity of pain), compared to the conventional treatment, in children who suffered from FAPDs measure: To measure daily pain score in children with and without FAPDs measure: To measure daily pain score in children with and without FAPDs measure: To measure daily pain score in children with and without FAPDs measure: To compare the diversity of fecal microbiota in children with FAPDs who took probiotics and those who did not sex: ALL minimumAge: 6 Years maximumAge: 15 Years stdAges: CHILD facility: Atchariya Chanpong status: RECRUITING city: Songkhla country: Thailand name: Atchariya Chanpong, M.D, Ph.D. role: CONTACT phone: +6674451250 email: atchariya.c@psu.ac.th lat: 7.19882 lon: 100.5951 hasResults: False
nctId: NCT06310720 id: 23-10026618 briefTitle: Postpartum Video Education in High Risk Populations overallStatus: NOT_YET_RECRUITING date: 2024-03 date: 2024-12 date: 2024-12 date: 2024-03-15 date: 2024-03-15 name: Weill Medical College of Cornell University class: OTHER briefSummary: This is a prospective, single-center, randomized control study to determine if video education at the time of postpartum discharge improves patient knowledge on the warning signs for the top three causes of severe maternal morbidity (infection, hemorrhage, and blood pressure disorders) in the first seven days following delivery for self-identified, Black, Latinx, other with two or more self-identified races, Medicaid, and/or uninsured postpartum individuals. Participants will be randomized to written discharge education + video education (intervention) vs standard discharge education (control). They will complete a baseline questionnaire and a post-discharge education questionnaire during their postpartum stay to assess for knowledge improvement. The investigators hypothesize that video education will improve patient's knowledge of severe maternal morbidity warning signs. conditions: Postpartum Hemorrhage conditions: Postpartum Depression conditions: Postpartum Sepsis conditions: Postpartum Preeclampsia conditions: Patient Empowerment conditions: Patient Education conditions: Postpartum Care studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: NONE count: 150 type: ESTIMATED name: Video Education measure: Change in baseline and post-education questionnaire score measure: Change in post-education and post-discharge questionnaire score measure: Number of participants who attended 6 week postpartum visit measure: Healthcare utilization: Number of clinic visits measure: Healthcare utilization: Number of phone calls measure: Healthcare utilization: Number of urgent care/emergency room visits measure: Mean difference in patient satisfaction rating sex: FEMALE minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Alexandra Cohen Hospital for Women and Newborns city: New York state: New York zip: 10065 country: United States name: Heather Lipkind, MD, MSce role: CONTACT phone: 212-746-3045 email: hlipkind@weill.cornell.edu name: Heather Lipkind, MD, MSce role: PRINCIPAL_INVESTIGATOR lat: 40.71427 lon: -74.00597 hasResults: False
nctId: NCT06310707 id: EU RCT: ePatch vs 24h Holter id: 2022-A02338-35 type: OTHER domain: ANSM, French competent authority id: EA4/071/23 type: OTHER domain: German Ethics Committee_Charité Universitätsmedizin Berlin briefTitle: Arrhythmia Identification in Syncope Patients: ePatch® Versus 24h Holter overallStatus: RECRUITING date: 2023-11-09 date: 2025-04 date: 2025-08 date: 2024-03-15 date: 2024-03-15 name: Philips Clinical & Medical Affairs Global class: INDUSTRY briefSummary: This study is a Multi-center, prospective, randomized, unblinded, two-arm study to assess if 7-days of cardiac monitoring using the ePatch Holter results in identification of more clinically actionable arrythmia for patients with symptoms of syncope than standard 24 hour Holter monitoring. conditions: Arrythmia conditions: Syncope studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Multi-center, prospective, randomized, unblinded, two-arm study, to include approximately 128 subjects treated with the ePatch Extended Wear Holter (worn for 7 days) and approximately 128 subjects treated with a Standard Wear Holter (worn for 24 hours). Randomization will be balanced for gender. primaryPurpose: DIAGNOSTIC masking: NONE count: 128 type: ESTIMATED name: ePatch ® Extended Wear Holter (EWH) measure: Diagnostic yield (frequency) of clinically actionable arrythmia measure: Number of Atrial Fibrillation (AF) diagnoses > 30 seconds measure: Occurrence of symptomatic events measure: Number of Clinically actionable arrhythmia measure: Patient Quality of Life as measured by EQ-5D-5L measure: Patient Quality of Life as measured by Patient Experience Survey measure: Cost related to cardiac monitoring measure: Time Holter is worn/ removed sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Hospices Civils de Lyon - Hôpital Cardiologique Louis Pradel status: RECRUITING city: Bron zip: 69677 Cedex country: France name: Philippe Chevalier, MD PhD role: CONTACT phone: +33.472.357.027 email: philippe.chevalier@chu-lyon.fr name: Philippe Chevalier, MD PhD role: PRINCIPAL_INVESTIGATOR lat: 45.73333 lon: 4.91667 facility: Deutsches Herzzentrum der Charité (DHZC) - Campus Benjamin Franklin status: NOT_YET_RECRUITING city: Berlin zip: D-12203 country: Germany name: Tharusan Thevathasan, MD role: CONTACT phone: +49 1577 4407864 email: tharusan.thevathasan@dhzc-charite.de name: Tharusan Thevathasan, MD role: PRINCIPAL_INVESTIGATOR lat: 52.52437 lon: 13.41053 hasResults: False
nctId: NCT06310694 id: EGE-HEM-SL-01 briefTitle: Additional Circular Dressing Material overallStatus: COMPLETED date: 2023-04-27 date: 2023-09-30 date: 2023-12-30 date: 2024-03-15 date: 2024-03-15 name: Ege University class: OTHER briefSummary: The study was conducted to determine the effect of fixing peripheral intravenous catheter (PIVC) with additional circular dressing material on the duration of PIVC stay and complications related to peripheral intravenous catheterization. In our study, a comparison was made of PIVCs applied to patients in the control (fixation of PIVC with a sterile transparent dressing) and intervention (fixation of PIVC with a sterile transparent dressing and application of an elastane circular dressing on it) groups in a public hospital in Turkey. All-cause PIVC failure was significantly higher in the intervention group (70.2%) compared to the control group (45.5%). It has been determined that fixing the PIVC with additional circular dressing material prolongs the duration of PIVC stay at the site. conditions: Nurse's Role studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: In our study, a comparison was made of PIVCs applied to patients in the control (fixation of PIVC with a sterile transparent dressing) and intervention (fixation of PIVC with a sterile transparent dressing and application of an elastane circular dressing on it) groups. primaryPurpose: SUPPORTIVE_CARE masking: NONE count: 91 type: ACTUAL name: intervention group (Elastane circular dressing on sterile transparent dressing) measure: Skin Penetration Difficulty Rating Scale measure: Visual Infusion Phlebitis Diagnostic Scale measure: Infiltration Rating Scale measure: Data Collection Form for the Patient Who Had a Peripheral Intravenous Catheter sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Şeyma Turan city: Turgutlu state: Manisa zip: 45400 country: Turkey lat: 38.49533 lon: 27.6997 hasResults: False
nctId: NCT06310681 id: ETH2223-2528 briefTitle: Pilot Testing of a Co-adapted Group Programme for Parents/Carers of Children With Complex Neurodisability acronym: ENCOMPASS overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2024-10 date: 2024-12 date: 2024-03-15 date: 2024-03-15 name: City, University of London class: OTHER briefSummary: The goal of this pilot feasibility study is to test a co-adapted community-based group programme ("Encompass") with parents/carers of children with complex neurodisability under 5 years of age in East London in the UK.
The groups will be facilitated by a healthcare professional and a parent with lived experience. They will also be interviewed about their experiences after the groups have been completed. conditions: Complex Neurodevelopmental Disorder conditions: Cerebral Palsy studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: SUPPORTIVE_CARE masking: NONE count: 28 type: ESTIMATED name: "Encompass" group programme measure: Group Attendance measure: Recruitment - percentage of eligible participants who consent to take part measure: Follow-up response rate-self-complete outcomes questionnaire(s) measure: Fidelity - delivery on items described in the Fidelity Checklist measure: Family Empowerment Scale (FES) measure: Power Ladder Question (PLQ) measure: Parent Patient Activation Measure (P-PAM) measure: Warwick-Edinburgh Mental Wellbeing Scale (WEMWBS) measure: Parent/carer Quality of Life - EuroQoL-5D-5-level (EQ-5D-5L) measure: Parent/carer Needs and Goals measure: Childhood Cost Calculator (C3) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Barts Health NHS Trust, Children's Occupational Therapy, Mile End Hospital city: London zip: E1 4EH country: United Kingdom name: Frances Badenhorst role: CONTACT lat: 51.50853 lon: -0.12574 facility: East London NHS Foundation Trust, Specialist Children's and Young People's Services city: London zip: E15 4PT country: United Kingdom name: Melissa Homer role: CONTACT lat: 51.50853 lon: -0.12574 hasResults: False
nctId: NCT06310668 id: CBT IN substance use disorder briefTitle: Has CBT an Effect on Emotional Intelligence in Patients With Substance Use Disorder? overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2024-09 date: 2024-10 date: 2024-03-15 date: 2024-03-15 name: Egyptian Medical Syndicate class: OTHER briefSummary: Aim of the study: In this study, the change in emotional intelligence will be assessed before and after group CBT sessions in male patients with substance use disorder in the inpatient department of the addiction unit at Mansoura University Hospital. conditions: Substance Use Disorders studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: randomized clinical trial primaryPurpose: TREATMENT masking: NONE count: 84 type: ESTIMATED name: group cognitive behavioral therapy sessions measure: emotional intelligence sex: MALE minimumAge: 18 Years maximumAge: 55 Years stdAges: ADULT hasResults: False
nctId: NCT06310655 id: 202403078 briefTitle: Online Proton Adaptive Radiotherapy acronym: PARTy overallStatus: NOT_YET_RECRUITING date: 2024-04-30 date: 2025-05-15 date: 2025-08-31 date: 2024-03-15 date: 2024-04-11 name: Washington University School of Medicine class: OTHER briefSummary: This is a pilot study evaluating the feasibility of daily online adaptive planning for patients undergoing proton radiation therapy.
Patients undergoing proton radiation therapy normally undergo extensive pre-planning for their treatment. However, accounting for uncertainties in treatment delivery remains a challenge for a variety of reasons, such as differences in patient anatomy from pre-planning to the day of treatment. Online adaptive planning is a process consisting of generating the original pre-plan on the patient on a treatment day, assessing the pre-plan's coverage and safety, and if changes are needed, the plan is changed in order to optimize the treatment while the patient is still on the treatment table. This study is assessing the feasibility and safety of this approach in order to gather data for a larger trial. conditions: Solid Tumor studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: All patients will receive 5 fractions of proton radiotherapy for their cancer. At the time of each fraction, the initial pre-plan will be compared to the newly generated adapted plan, and the optimal treatment will be administered. primaryPurpose: TREATMENT masking: NONE count: 10 type: ESTIMATED name: Proton SBRT measure: Feasibility of online proton adaptive radiotherapy measure: Safety of online proton adaptive radiotherapy as measured by the amount of grade 2 and higher radiation-related toxicities sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Washington University School of Medicine city: Saint Louis state: Missouri zip: 63110 country: United States name: Allen Mo, M.D., Ph.D. role: CONTACT phone: 314-717-2320 email: amo@wustl.edu name: Allen Mo, M.D., Ph.D. role: PRINCIPAL_INVESTIGATOR name: Hyun Kim, M.D. role: SUB_INVESTIGATOR name: Stephanie Perkins, M.D. role: SUB_INVESTIGATOR name: Joshua Schiff, M.D. role: SUB_INVESTIGATOR name: Weiren Liu, M.D. role: SUB_INVESTIGATOR name: Hailei Zhang, Ph.D. role: SUB_INVESTIGATOR name: Yi Huang, M.S. role: SUB_INVESTIGATOR name: Robbie Beckert role: SUB_INVESTIGATOR name: Eric Laugeman, M.S. role: SUB_INVESTIGATOR name: Farideh Pak, Ph.D. role: SUB_INVESTIGATOR name: Mike Watts, M.S. role: SUB_INVESTIGATOR name: Xiandong Zhao, Ph.D. role: SUB_INVESTIGATOR name: Tianyu Zhao, Ph.D. role: SUB_INVESTIGATOR lat: 38.62727 lon: -90.19789 hasResults: False
nctId: NCT06310642 id: 2020-217 briefTitle: Efficacy of Prophylactic Treatment of Oral Prochlorperazine for Acute Mountain Sickness acronym: PAMS overallStatus: COMPLETED date: 2021-05-20 date: 2023-03-13 date: 2023-03-13 date: 2024-03-15 date: 2024-03-15 name: CHRISTUS Health class: OTHER briefSummary: A field-based trial was conducted to determine if oral prochlorperazine demonstrates efficacy in the prophylactic treatment of AMS, and/or decreases the incidence of the symptoms of acute mountain sickness including headache, GI symptoms, fatigue and dizziness based on data collected in the Lake Louise AMS score. conditions: AMS conditions: Acute Mountain Sickness studyType: INTERVENTIONAL phases: PHASE4 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Enrolled a cohort of consenting, healthy subjects aged \>17 years. Thirty subjects enrolled in the study. 15 subjects received prochlorperazine. 15 subjects received placebo. primaryPurpose: TREATMENT masking: SINGLE maskingDescription: Patients were blinded in this study. whoMasked: PARTICIPANT count: 30 type: ACTUAL name: Immediate descent from altitude. name: Diphenhydramine name: Prochlorperazine 10 mg measure: Mean Lake Louise Acute Mountain Sickness Score (LLAMS) was utilized to compare symptoms of acute mountain sickness between the prochlorperazine and placebo groups measure: Subjects meeting Lake Louise Acute Mountain Sickness Score (LLAMS) criteria for acute mountain sickness between the prochlorperazine and placebo groups sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: CHRISTUS Health-Texas A&M Spohn Emergency Medicine Residency city: Corpus Christi state: Texas zip: 78405 country: United States lat: 27.80058 lon: -97.39638 hasResults: False
nctId: NCT06310629 id: CMUH112-REC3-163 briefTitle: Oxygenation Efficacy of "Intrinseque Health" Non-Rebreathing Mask ("IHNRM") overallStatus: RECRUITING date: 2024-02-22 date: 2025-02-21 date: 2025-05-21 date: 2024-03-15 date: 2024-03-15 name: China Medical University Hospital class: OTHER briefSummary: Based on early bench-testing data and subsequent clinical case studies in the U.S., "Intrinseque Health" non-rebreathing mask (IHNRM) has delivered virtual elimination of air entrainment and preferential delivery of all available oxygen first into the alveolar spaces by sequential opening of valves in its controller manifold, even at oxygen flow as low as 10 LPM, patient can attain high alveolar oxygen concentration of 75% or more-far higher than attainable with face mask or nasal cannula.